F-18-Fluorodeoxyglucose Positron Emission Tomography Imaging-Assisted Management of Patients With Severe Left Ventricular Dysfunction and Suspected Coronary Disease. A Randomized, Controlled Trial (PARR-2)

Journal of the American College of Cardiology

Volumn 50, Issue 20, 2007, Pages 2002-2012

  Beanlands, Rob S B ^a,j   Nichol, Graham ^i,j   Huszti, Ella ^f,j   Humen, Dennis ^b,j   Racine, Normand ^g,j   Freeman, Michael ^c,j   Gulenchyn, Karen Y ^e,j   Garrard, Linda ^a,j   deKemp, Robert ^a,j   Guo, Ann ^a,j   Ruddy, Terrence D ^a,j   Benard, Francois ^h,j   Lamy, André ^e,j   Iwanochko, Robert M ^d,j  

^a UNIVERSITY OF OTTAWA HEART INSTITUTE   (Canada)

^b LONDON HEALTH SCIENCES CENTRE   (Canada)

^c ST MICHAEL'S HOSPITAL   (Canada)

^d UNIVERSITY HEALTH NETWORK   (Canada)

^e the Division of Cardiac Surgery   (Canada)

^f MCGILL UNIVERSITY   (Canada)

^g MONTREAL HEART INSTITUTE   (Canada)

^h CENTRE HOSPITALIER UNIVERSITAIRE DE SHERBROOKE   (Canada)

ⁱ UNIVERSITY OF WASHINGTON   (United States)

^j UNIVERSITY OF OTTAWA   (Canada)

more..

Author keywords

[No Author keywords available]

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

ADULT; AGED; ANGIOCARDIOGRAPHY; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; FEMALE; HEART DEATH; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE FAILURE; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REVASCULARIZATION;

AGED; CORONARY DISEASE; DEATH; DISEASE MANAGEMENT; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; SURVIVAL RATE; VENTRICULAR DYSFUNCTION, LEFT;

EID: 35748943458     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2007.09.006     Document Type: Article

References (36)

1. Pfeffer J., McMurray J., Velazquez E., et al. Valsartan, captopril or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Eng J Med 349 (2003) 1893-1906
2. Bristow M., Saxon L.A., Boehmer J., et al., Comparison of Medical Therapy, Pacing and Defibrillation in Heart Failure (COMPANION) Investigators. Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Eng J Med 350 (2004) 2140-2150
3. Cleland J., Daubert J.C., Erdmann E., et al., Cardiac Resynchronization-Heart Failure (CARE-HF) Study Investigators. The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med 352 (2005) 1539-1549
4. Jessup M., and Brozena S. Heart failure. N Engl J Med 348 (2003) 2007-2018
5. Konstam M.A. Progress in heart failure management?. Lessons from the real world. Circulation 102 (2000) 1076-1078
6. Khand A., Gemmel I., Clark A., and Cleland J. Is the prognosis of heart failure improving?. J Am Coll Cardiol 36 (2000) 2284-2286
7. Kron I.L., Flanagan T.L., Blackbourne L.H., Schroeder R.A., and Nolan S.P. Coronary revascularization rather than cardiac transplantation for chronic ischemic cardiomyopathy. Ann Surg 210 (1989) 348-352
8. Tjan T., Kondruweit M., Scheld H., et al. The bad ventricle-revascularization versus transplantation. Thorac Cardiovasc Surg 48 (2000) 9-14
9. Jones R. Is it time for a randomized trial of surgical treatment of ischemic heart failure?. J Am Coll Cardiol 37 (2001) 1210-1213
10. Bax J.J., Poldermans D., Elhendy A., Boersma E., and Rahimtoola S. Sensitivity, specificity, and predictive accuracies of various noninvasive techniques for detecting hibernating myocardium. Curr Probl Cardiol 26 (2001) 141-186
11. Barrington S., Chambers J., Hallett W., O'Doherty M., Roxburgh J., and Nunan T. Comparison of sestamibi, thallium, echocardiography and PET for the detection of hibernating myocardium. Eur J Nucl Med Mol Imaging 31 (2004) 355-361
12. Bax J.J., Maddahi J., Poldermans D., et al. Preoperative comparison of different noninvasive strategies for predicting improvement in left ventricular function after coronary artery bypass grafting. Am J Cardiol 92 (2003) 1-4
13. Wiggers H., Egeblad H., Nielsen T., and Botker H. Prediction of reversible myocardial dysfunction by positron emission tomography, low-dose dobutamine echocardiography, resting ECG, and exercise testing. Cardiology 96 (2001) 32-37
14. Di Carli M.F., Davidson M., Little R., et al. Value of metabolic imaging with positron emission tomography for evaluating prognosis in patients with coronary artery disease and left ventricular dysfunction. Am J Cardiol 73 (1994) 527-533
15. Eitzman D., Al-Aouar Z., Kanter H.L., et al. Clinical outcome of patients with advanced coronary artery disease after viability studies with positron emission tomography. J Am Coll Cardiol 20 (1992) 559-565
16. Lee K.S., Marwick T.H., Cook S.A., et al. Prognosis of patients with left ventricular dysfunction, with and without viable myocardium after myocardial infarction: relative efficacy of medical therapy and revascularization. Circulation 90 (1995) 2687-2694
17. Allman K.C., Shaw L., Hachamovitch R., and Udelson J. Myocardial viability testing and impact of revascularization on prognosis in patients with coronary artery disease and left ventricular dysfunction: a meta-analysis. J Am Coll Cardiol 39 (2002) 1151-1158
18. Rohatgi R., Epstein S., Henriquez J., et al. Utility of positron emission tomography in predicting cardiac events and survival in patients with coronary artery disease and severe left ventricular dysfunction. Am J Cardiol 87 (2001) 1096-1099 A6
19. Desideri A., Cortigiani L., Christen A., et al. The extent of perfusion-F18-fluorodeoxyglucose positron emission tomography mismatch determines mortality in medically treated patients with chronic ischemic left ventricular dysfunction. J Am Coll Cardiol 46 (2005) 1264-1269
20. Beanlands R., Dick A., Chow B., et al. CCS; CAR; CANM; CNCS; and CanSCMR position statement on advanced noninvasive cardiac imaging using positron emission tomography, magnetic resonance imaging and multi-detector computed tomographic angiography in the diagnosis and evaluation of ischemic heart disease. Can J Cardiol 23 (2007) 107-119
21. Beanlands R., Nichol G., Ruddy T.D., et al. Evaluation of outcome and cost-effectiveness using an FDG PET-guided approach to management of patients with coronary disease and severe left ventricular dysfunction (PARR-2): rationale, design, and methods. Control Clin Trials 24 (2003) 776-794
22. Beanlands R.S., Ruddy T.D., deKemp R.A., et al. Positron emission tomography and recovery following revascularization (PARR-1): the importance of scar and the development of a prediction rule for the degree of recovery of left ventricular function. J Am Coll Cardiol 40 (2002) 1735-1743
23. Schelbert H., Beanlands R., Bengel F., et al. PET myocardial perfusion and glucose metabolism imaging: part 2-guidelines for interpretation and reporting. J Nucl Cardiol 10 (2003) 557-571
24. Vitale G.D., deKemp R.A., Ruddy T.D., Williams K., and Beanlands R.S. Myocardial glucose utilization and optimization of (18)F-FDG PET imaging in patients with non-insulin-dependent diabetes mellitus, coronary artery disease, and left ventricular dysfunction. J Nucl Med 42 (2001) 1730-1736
25. O'Brien P.C., and Fleming T.R. A multiple testing procedure for clinical trials. Biometrics 35 (1979) 549-556
26. Tarakji K., Brunken R.C., McCarthy P.M., et al. Myocardial viability testing and the effect of early intervention in patients with advanced left ventricular systolic dysfunction. Circulation 113 (2006) 230-237
27. Bax J.J., Schinkel A., Boersma E., et al. Early versus delayed revascularization in patients with ischemic cardiomyopathy and substantial viability: impact on outcome. Circulation 108 (2003) II39-II42
28. Beanlands R.S., Hendry P.J., Masters R.G., deKemp R.A., Woodend K., and Ruddy T.D. Delay in revascularization is associated with increased mortality rate in patients with severe left ventricular dysfunction and viable myocardium on fluorine 18-fluorodeoxyglucose positron emission tomography imaging. Circulation 98 (1998) II51-II56
29. Siebelink H.-M., Blanksma P.K., Crijns H., et al. No difference in cardiac event-free survival between positron emission tomography-guided and single-photon emission computed tomography-guided management. A prospective, randomized comparison of patients with suspicion of jeopardized myocardium. J Am Coll Cardiol 37 (2001) 81-88
30. Joyce D., Loebe M., Noon G., et al. Revascularization and ventricular restoration in patients with ischemic heart failure: the STICH trial. Curr Opin Cardiol 18 (2003) 454-457
31. Cleland J., Freemantle N., Ball S., et al. The heart failure revasculisation trial (HEART): rationale, design and methodology. Eur J Heart Fail 5 (2003) 295-303
32. Rizzello V., Poldermans D., Schinkel A., et al. Long term prognostic value of myocardial viability and ischaemia during dobutamine stress echocardiography in patients with ischaemic cardiomyopathy undergoing coronary revascularisation. Heart 92 (2006) 239-244
33. Di Carli M., Hachamovitch R., and Berman D.S. The art and science of predicting postrevascularization improvement in left ventricular (LV) dysfunction in patients with severely depressed LV dysfunction. J Am Coll Cardiol 40 (2002) 1744-1747
34. Schwaiger M., Ziegler S., and Nekolla S. PET/CT: challenge for nuclear cardiology. J Nucl Med 46 (2005) 1664-1678
35. Sadowski E.A., Bennett L.K., Chan M.R., et al. Nephrogenic systemic fibrosis: risk factors and incidence estimation. Radiology 243 (2007) 148-157
36. Douglas P.S. Improving imaging: our professional imperative. J Am Coll Cardiol 48 (2006) 2152-2155